Clinical trials: Alzheimer Disease 1
Alzheimer Disease
The Efficacy of Traditional Chinese Herbal Medicine for Alzheimer's Disease
This randomized, double-blinded, placebo-controlled, crossover clinical trial aims to investigate the effect of VGH-AD1, a scientific Chinese medicine powder prescription, on patients with Alzheimer's disease.
- Trial name
- NCT04249869
- Testing
- VGH-AD1
- Volunteers
- 28 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Alzheimer's Disease
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's disease (AD).
- Trial name
- NCT05463731
- Testing
- Remternetug (IV), Remternetug (SC)
- Where
- 76 sites in United States, Japan
- Volunteers
- 1,667 people
- Sponsor
- Eli Lilly and Company
Healthy Participants, Alzheimer's Disease Dementia
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
The primary purpose of the study is to evaluate the safety and tolerability of emraclidine administered orally to healthy elderly participants in Part A (multiple ascending doses) and participants with dementia due to Alzheimer's…
- Trial name
- NCT05644977
- Testing
- Emraclidine
- Where
- 11 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- AbbVie
Alzheimer Disease
Far Infrared Treatment for Alzheimer's Disease
Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.
- Trial name
- NCT00599469
- Testing
- Far Infrared Radiation (5μm to 20μm wavelength)
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- GAAD Medical Research Institute Inc.
Alzheimer´s Disease
Treatment With Copper in Patients With Mild Alzheimer´s Dementia
The efficacy of 8 mg of copper daily regarding cognitive function, content of beta amyloid protein in the CSF and volumetric changes in the brain will be examined in a first double-blind, placebo-controlled human clinical trial…
- Trial name
- NCT00608946
- Testing
- copper
- Volunteers
- 68 people
- Sponsor
- University Hospital, Saarland
Alzheimer's Disease
A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous administration of SHR-1707 in healthy young adult and elderly subjects.
- Trial name
- NCT04973189
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Healthy Participants, Alzheimer Disease
A Phase 1 Study to Assess the Safety and Effects of Single and Multiple Doses of KS101 in Healthy Volunteers
This study is the first clinical trial involving study drug KS101. The goal of this clinical trial is to investigate whether KS101 is safe, whether it causes side effects, and how KS101 is broken down in the body, in healthy…
- Conditions
- Healthy Participants, Alzheimer Disease, Chronic Kidney Disease
- Trial name
- NCT07143331
- Testing
- Part 1 KS101, Part 2 with Food, Part 2 without food
- Where
- Australia
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Klotho Sciences Australia Pty Ltd.
Alzheimer Disease
Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers
This study is to evaluate the safety and tolerability of single dose of GB-5001 (donepezil) IM and SC depot in healthy male Adults.
- Trial name
- NCT06127368
- Testing
- GB-5001A, GB-5001D, Oral cohort
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- G2GBio, Inc.
Alzheimer's Disease
Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease
This combined phase 1/2a clinical trial is to investigate the safety, dose limiting toxicity (DLT), and exploratory efficacy of three repeated intraventricular administrations of NEUROSTEM® (human umbilical cord blood-derived…
- Trial name
- NCT02054208
- Testing
- human umbilical cord blood derived mesenchymal stem cells, Normal saline 2mL
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Medipost Co Ltd.
Alzheimer Disease
Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production
Phase 1, Single-center, Open-label Study, Healthy Adult Male Subjects. Part 1:Single-dose, Placebo-controlled, 3-Way Crossover PK Study Part 2: Single dose 2-way comparator PK Study
- Trial name
- NCT03971123
- Testing
- Tricaprilin
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Cerecin
Alzheimer's Disease
Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers
Phase 1A SAD: Five or more cohorts of 8 healthy volunteers (HVs) will receive a single IV bolus injection of study drug or placebo. The first 4 cohorts will be male only.
- Trial name
- NCT05965414
- Testing
- CS6253 Solution for Injection
- Where
- Spain
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Artery Therapeutics, Inc.
Alzheimer Disease, Dementia
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
The goal of this Phase 2 Open Label study is to evaluate long-term safety, tolerability, and efficacy of XPro1595 on measures of cognition, function and brain quality in individuals with Alzheimer's Disease.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05522387
- Testing
- XPro1595
- Where
- 4 sites in Australia
- Volunteers
- 11 people
- Sponsor
- Inmune Bio, Inc.
Alzheimer Disease
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
The purpose of the study is to evaluate the safety and tolerability of multiple doses of NPT088 in patients with mild to moderate probable Alzheimer's Disease.
- Trial name
- NCT03008161
- Testing
- NPT088
- Where
- 23 sites in United States
- Volunteers
- 83 people
- Sponsor
- Proclara Biosciences, Inc.
Alzheimer's Disease, Mild Cognitive Impairment
A Light Exposure Tracker Designed to Improve Circadian Rhythms - Aim 1
The purpose of this research study is to investigate the relationship between reminder messages sent via text and compliance with a daily morning light intervention designed to advance the circadian clock.
- Trial name
- NCT06356337
- Testing
- Light goggles, Daily reminder test message
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer Disease
A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects
A randomized, double-blind, placebo-controlled, single dose escalation phase 1 study to access the Pharmacokinetics and Pharmacodynamics of Single Intravenous Administration of SHR-1707
- Trial name
- NCT04745104
- Testing
- SHR-1707
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
EEG Brain Oscillations, Alzheimer's Disease (AD) and Related Disorders
Efficacy of Gamma Auditory Stimulation for Cognitive Decline in Older Adults (Study 1)
Animal studies have shown that 40 Hz auditory stimulation alone can improve spatial memory and reduce Aβ deposition. However, human studies using 40 Hz auditory stimulation alone remain limited.
- Conditions
- EEG Brain Oscillations, Alzheimer's Disease (AD) and Related Disorders, Cognitive Dysfunction
- Trial name
- NCT07087951
- Testing
- Gamma auditory stimulation device (active setting)
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Chang Gung Memorial Hospital
Alzheimer Disease
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
- Trial name
- NCT06511570
- Testing
- sabirnetug (ACU193), Sabirnetug + rHuPH20
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Acumen Pharmaceuticals
AL Amyloidosis
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Light chain (AL) amyloidosis is a bone marrow disorder that affects a wide range of organs that can lead to organ dysfunction and death.
- Trial name
- NCT03236792
- Testing
- Ixazomib, Cyclophosphamide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer's Disease, Healthy Participants
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
This is a Phase 1/1b, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL921 in healthy…
- Trial name
- NCT07758595
- Testing
- DNL921
- Where
- United Kingdom
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Denali Therapeutics Inc.
Alzheimer Disease 1
Progress of Mild Alzheimer's Disease in Participants on Acupuncture Versus Sham Acupuncture
To determine if adjunctive acupuncture acts as an AD treatment rather than a placebo.
- Trial name
- NCT05078944
- Testing
- Active acupuncture, Donepezil Hydrochloride
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Institute of Acupuncture, Moxibustion and Meridian